Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromes

Journal of Leukocyte Biology

Volumn 102, Issue 2, 2017, Pages 209-219

  Cull, Alyssa H ^a   Rauh, Michael J ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Cancer; Inflammation; Leukemogenesis; Myeloid cells

Indexed keywords

CRYOPYRIN; DNA METHYLTRANSFERASE 3A; INTERFERON; MICRORNA 145; MICRORNA 146A; TOLL LIKE RECEPTOR 4;

BONE MARROW DEPRESSION; CANCER IMMUNOTHERAPY; CELL DEATH; CHROMOSOME 5Q; CHROMOSOME DELETION; DYSPLASIA; EPIGENETICS; GENE MUTATION; HAPLOINSUFFICIENCY; HEMATOPOIESIS; HUMAN; IMMUNE DYSREGULATION; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; BONE MARROW; GENETICS; IMMUNOLOGY; MUTATION; PATHOLOGY;

BONE MARROW; HUMANS; MUTATION; MYELODYSPLASTIC SYNDROMES;

EID: 85026736953     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.5RI0317-083R     Document Type: Review

References (124)

1. Murati, A., Brecqueville, M., Devillier, R., Mozziconacci, M. J., Gelsi-Boyer, V., Birnbaum, D. (2012) Myeloid malignancies: mutations, models and management. BMC Cancer 12, 304.
2. Swerdlow, S. H. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer, Lyon, France.
3. Sekeres, M. A. (2010) The epidemiology of myelodysplastic syndromes. Hematol. Oncol. Clin. North Am. 24, 287–294.
4. Wilson, A. B., Neogi, T., Prout, M., Jick, S. (2014) Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the general practice research database. Cancer Epidemiol. 38, 544–549.
5. Strom, S. S., Gu, Y., Gruschkus, S. K., Pierce, S. A., Estey, E. H. (2005) Risk factors of myelodysplastic syndromes: a case-control study. Leukemia 19, 1912–1918.
6. Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., Le Beau, M. M., Slovak, M. L., Krieger, O., Luebbert, M., Maciejewski, J., Magalhaes, S. M., Miyazaki, Y., Pfeilstöcker, M., Sekeres, M., Sperr, W. R., Stauder, R., Tauro, S., Valent, P., Vallespi, T., van de Loosdrecht, A. A., Germing, U., Haase, D. (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120, 2454–2465.
7. Heaney, M. L., Golde, D. W. (1999) Myelodysplasia. N. Engl. J. Med. 340, 1649–1660.
8. Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G., Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89, 2079–2088.
9. Shukron, O., Vainstein, V., Kündgen, A., Germing, U., Agur, Z. (2012) Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database. Am. J. Hematol. 87, 853–860.
10. Tefferi, A., Vardiman, J. W. (2009) Myelodysplastic syndromes. N. Engl. J. Med. 361, 1872–1885.
11. Pardanani, A. (2012) Systemic mastocytosis: disease overview, pathogenesis, and treatment. Hematol. Oncol. Clin. North Am. 26, 1117–1128.
12. Bacher, U., Haferlach, T., Schnittger, S., Kreipe, H., Kröger, N. (2011) Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. Br. J. Haematol. 153, 149–167.
13. Adès, L., Itzykson, R., Fenaux, P. (2014) Myelodysplastic syndromes. Lancet 383, 2239–2252.
14. Patnaik, M. M., Parikh, S. A., Hanson, C. A., Tefferi, A. (2014) Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br. J. Haematol. 165, 273–286.
15. Raza, A., Gezer, S., Mundle, S., Gao, X. Z., Alvi, S., Borok, R., Rifkin, S., Iftikhar, A., Shetty, V., Parcharidou, A., Loew, J., Marcus, B., Khan, Z., Chaney, C., Showel, J., Gregory, S., Preisler, H. (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86, 268–276.
16. Raza, A., Galili, N. (2012) The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat. Rev. Cancer 12, 849–859.
17. Parker, J. E., Mufti, G. J., Rasool, F., Mijovic, A., Devereux, S., Pagliuca, A. (2000) The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 96, 3932–3938.
18. Jilg, S., Reidel, V., Müller-Thomas, C., König, J., Schauwecker, J., Höckendorf, U., Huberle, C., Gorka, O., Schmidt, B., Burgkart, R., Ruland, J., Kolb, H. J., Peschel, C., Oostendorp, R. A., Götze, K. S., Jost, P. J. (2016) Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia 30, 112–123.
19. Gañán-Gómez, I., Wei, Y., Starczynowski, D. T., Colla, S., Yang, H., Cabrero-Calvo, M., Bohannan, Z. S., Verma, A., Steidl, U., Garcia-Manero, G. (2015) Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia 29, 1458–1469.
20. Corey, S. J., Minden, M. D., Barber, D. L., Kantarjian, H., Wang, J. C., Schimmer, A. D. (2007) Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat. Rev. Cancer 7, 118–129.
21. + T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br. J. Haematol. 145, 64–72.
22. Raaijmakers, M. H. (2014) Disease progression in myelodysplastic syndromes: do mesenchymal cells pave the way? Cell Stem Cell 14, 695–697.
23. Chen, X., Eksioglu, E. A., Zhou, J., Zhang, L., Djeu, J., Fortenbery, N., Epling-Burnette, P., Van Bijnen, S., Dolstra, H., Cannon, J., Youn, J. I., Donatelli, S. S., Qin, D., De Witte, T., Tao, J., Wang, H., Cheng, P., Gabrilovich, D. I., List, A., Wei, S. (2013) Induction of myelodysplasia by myeloid-derived suppressor cells. J. Clin. Invest. 123, 4595–4611.
24. + regulatory T cells in myelodysplastic syndrome (MDS). Blood 110, 847–850.
25. Mailloux, A. W., Sugimori, C., Komrokji, R. S., Yang, L., Maciejewski, J. P., Sekeres, M. A., Paquette, R., Loughran, Jr., T. P., List, A. F., Epling-Burnette, P. K. (2012) Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J. Immunol. 189, 3198–3208.
26. Epling-Burnette, P. K., Bai, F., Painter, J. S., Rollison, D. E., Salih, H. R., Krusch, M., Zou, J., Ku, E., Zhong, B., Boulware, D., Moscinski, L., Wei, S., Djeu, J. Y., List, A. F. (2007) Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 109, 4816–4824.
27. Takeuchi, O., Akira, S. (2010) Pattern recognition receptors and inflammation. Cell 140, 805–820.
28. Maratheftis, C. I., Andreakos, E., Moutsopoulos, H. M., Voulgarelis, M. (2007) Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes. Clin. Cancer Res. 13, 1154–1160.
29. Kuninaka, N., Kurata, M., Yamamoto, K., Suzuki, S., Umeda, S., Kirimura, S., Arai, A., Nakagawa, Y., Suzuki, K., Kitagawa, M. (2010) Expression of Toll-like receptor 9 in bone marrow cells of myelodysplastic syndromes is down-regulated during transformation to overt leukemia. Exp. Mol. Pathol. 88, 293–298.
30. Wei, Y., Dimicoli, S., Bueso-Ramos, C., Chen, R., Yang, H., Neuberg, D., Pierce, S., Jia, Y., Zheng, H., Wang, H., Wang, X., Nguyen, M., Wang, S. A., Ebert, B., Bejar, R., Levine, R., Abdel-Wahab, O., Kleppe, M., Ganan-Gomez, I., Kantarjian, H., Garcia-Manero, G. (2013) Toll-like receptor alterations in myelodysplastic syndrome. Leukemia 27, 1832–1840.
31. Hofmann, W. K., de Vos, S., Komor, M., Hoelzer, D., Wachsman, W., Koeffler, H. P. (2002) Characterization of gene expression of CD34 cells from normal and myelodysplastic bone marrow. Blood 100, 3553–3560.
32. + cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 112, 3412–3424.
33. Gondek, L. P., Tiu, R., O’Keefe, C. L., Sekeres, M. A., Theil, K. S., Maciejewski, J. P. (2008) Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111, 1534–1542.
34. Velegraki, M., Papakonstanti, E., Mavroudi, I., Psyllaki, M., Tsatsanis, C., Oulas, A., Iliopoulos, I., Katonis, P., Papadaki, H. A. (2013) Impaired clearance of apoptotic cells leads to HMGB1 release in the bone marrow of patients with myelodysplastic syndromes and induces TLR4-mediated cytokine production. Haematologica 98, 1206–1215.
35. Rhyasen, G. W., Bolanos, L., Fang, J., Jerez, A., Wunderlich, M., Rigolino, C., Mathews, L., Ferrer, M., Southall, N., Guha, R., Keller, J., Thomas, C., Beverly, L. J., Cortelezzi, A., Oliva, E. N., Cuzzola, M., Maciejewski, J. P., Mulloy, J. C., Starczynowski, D. T. (2013) Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell 24, 90–104.
36. Dimicoli, S., Wei, Y., Bueso-Ramos, C., Yang, H., Dinardo, C., Jia, Y., Zheng, H., Fang, Z., Nguyen, M., Pierce, S., Chen, R., Wang, H., Wu, C., Garcia-Manero, G. (2013) Overexpression of the Toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes. PLoS One 8, e71120.
37. Varney, M. E., Niederkorn, M., Konno, H., Matsumura, T., Gohda, J., Yoshida, N., Akiyama, T., Christie, S., Fang, J., Miller, D., Jerez, A., Karsan, A., Maciejewski, J. P., Meetei, R. A., Inoue, J., Starczynowski, D. T. (2015) Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling. J. Exp. Med. 212, 1967–1985.
38. De Hollanda, A., Beucher, A., Henrion, D., Ghali, A., Lavigne, C., Lévesque, H., Hamidou, M., Subra, J. F., Ifrah, N., Belizna, C. (2011) Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res. (Hoboken) 63, 1188–1194.
39. Mekinian, A., Braun, T., Decaux, O., Falgarone, G., Toussirot, E., Raffray, L., Omouri, M., Gombert, B., De Wazieres, B., Buchdaul, A. L., Ziza, J. M., Launay, D., Denis, G., Madaule, S., Rose, C., Grignano, E., Fenaux, P., Fain, O.; Club Rhumatismes et Inflammation (CRI), Groupe Francophone des Myélodysplasies (GFM); Société Nationale Française de Médecine Interne (SNFMI). (2014) Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases. Medicine (Baltimore) 93, 1–10.
40. Al Ustwani, O., Ford, L. A., Sait, S. J., Block, A. M., Barcos, M., Vigil, C. E., Griffiths, E. A., Thompson, J. E., Wang, E. S., Ambrus, J. Jr., Wetzler, M. (2013) Myelodysplastic syndromes and autoimmune diseases–case series and review of literature. Leuk. Res. 37, 894–899.
41. Kristinsson, S. Y., Björkholm, M., Hultcrantz, M., Derolf, A. R., Landgren, O., Goldin, L. R. (2011) Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J. Clin. Oncol. 29, 2897–2903.
42. Titmarsh, G. J., McMullin, M. F., McShane, C. M., Clarke, M., Engels, E. A., Anderson, L. A. (2014) Community-acquired infections and their association with myeloid malignancies. Cancer Epidemiol. 38, 56–61.
43. Nakamura, F., Watanabe, T., Hori, K., Ohara, Y., Yamashita, K., Tsuji, Y., Ueda, Y., Mikami, S., Nakase, H., Chiba, T. (2009) Simultaneous occurrence of inflammatory bowel disease and myelodysplastic syndrome due to chromosomal abnormalities in bone marrow cells. Digestion 79, 215–219.
44. Starczynowski, D. T., Kuchenbauer, F., Argiropoulos, B., Sung, S., Morin, R., Muranyi, A., Hirst, M., Hogge, D., Marra, M., Wells, R. A., Buckstein, R., Lam, W., Humphries, R. K., Karsan, A. (2010) Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat. Med. 16, 49–58.
45. Filipowicz, W., Bhattacharyya, S. N., Sonenberg, N. (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 9, 102–114.
46. Taganov, K. D., Boldin, M. P., Chang, K. J., Baltimore, D. (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA 103, 12481–12486.
47. Hou, J., Wang, P., Lin, L., Liu, X., Ma, F., An, H., Wang, Z., Cao, X. (2009) MicroRNA-146a feedback inhibits RIG-I-dependent type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J. Immunol. 183, 2150–2158.
48. Lu, L. F., Boldin, M. P., Chaudhry, A., Lin, L. L., Taganov, K. D., Hanada, T., Yoshimura, A., Baltimore, D., Rudensky, A. Y. (2010) Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142, 914–929.
49. Boldin, M. P., Taganov, K. D., Rao, D. S., Yang, L., Zhao, J. L., Kalwani, M., Garcia-Flores, Y., Luong, M., Devrekanli, A., Xu, J., Sun, G., Tay, J., Linsley, P. S., Baltimore, D. (2011) miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J. Exp. Med. 208, 1189–1201.
50. Serbina, N. V., Jia, T., Hohl, T. M., Pamer, E. G. (2008) Monocyte-mediated defense against microbial pathogens. Annu. Rev. Immunol. 26, 421–452.
51. Swirski, F. K., Nahrendorf, M., Etzrodt, M., Wildgruber, M., Cortez-Retamozo, V., Panizzi, P., Figueiredo, J. L., Kohler, R. H., Chudnovskiy, A., Waterman, P., Aikawa, E., Mempel, T. R., Libby, P., Weissleder, R., Pittet, M. J. (2009) Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325, 612–616.
52. Tacke, F., Alvarez, D., Kaplan, T. J., Jakubzick, C., Spanbroek, R., Llodra, J., Garin, A., Liu, J., Mack, M., van Rooijen, N., Lira, S. A., Habenicht, A. J., Randolph, G. J. (2007) Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest. 117, 185–194.
53. Martin, A. P., Rankin, S., Pitchford, S., Charo, I. F., Furtado, G. C., Lira, S. A. (2008) Increased expression of CCL2 in insulin-producing cells of transgenic mice promotes mobilization of myeloid cells from the bone marrow, marked insulitis, and diabetes. Diabetes 57, 3025–3033.
54. Qian, B. Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., Pollard, J. W. (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475, 222–225.
55. Chasis, J. A., Mohandas, N. (2008) Erythroblastic islands: niches for erythropoiesis. Blood 112, 470–478.
56. Winkler, I. G., Sims, N. A., Pettit, A. R., Barbier, V., Nowlan, B., Helwani, F., Poulton, I. J., van Rooijen, N., Alexander, K. A., Raggatt, L. J., Lévesque, J. P. (2010) Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 116, 4815–4828.
57. Liu, Y. J., Kanzler, H., Soumelis, V., Gilliet, M. (2001) Dendritic cell lineage, plasticity and cross-regulation. Nat. Immunol. 2, 585–589.
58. Kitagawa, M., Kamiyama, R., Kasuga, T. (1993) Increase in number of bone marrow macrophages in patients with myelodysplastic syndromes. Eur. J. Haematol. 51, 56–58.
59. Ma, L., Delforge, M., van Duppen, V., Verhoef, G., Emanuel, B., Boogaerts, M., Hagemeijer, A., Vandenberghe, P. (2004) Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes. Leukemia 18, 1451–1456.
60. Pellagatti, A., Boultwood, J. (2015) The molecular pathogenesis of the myelodysplastic syndromes. Eur. J. Haematol. 95, 3–15.
61. Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., Zhao, D., Liu, Y., Wang, C., Zhang, X., Su, X., Liu, J., Ge, W., Levine, R. L., Li, N., Cao, X. (2015) Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 525, 389–393.
62. Turner, M. D., Nedjai, B., Hurst, T., Pennington, D. J. (2014) Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochim. Biophys. Acta 1843, 2563–2582.
63. Díaz-Muñoz, M. D., Osma-García, I. C., Cacheiro-Llaguno, C., Fresno, M., Iñiguez, M. A. (2010) Coordinated up-regulation of cyclooxygenase-2 and microsomal prostaglandin E synthase 1 transcription by nuclear factor kappa B and early growth response-1 in macrophages. Cell. Signal. 22, 1427–1436.
64. Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C. L., Sano, S., Muralidharan, S., Rius, C., Vuong, J., Jacob, S., Muralidhar, V., Robertson, A. A., Cooper, M. A., Andrés, V., Hirschi, K. K., Martin, K. A., Walsh, K. (2017) Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355, 842–847.
65. Ichiyama, K., Chen, T., Wang, X., Yan, X., Kim, B. S., Tanaka, S., Ndiaye-Lobry, D., Deng, Y., Zou, Y., Zheng, P., Tian, Q., Aifantis, I., Wei, L., Dong, C. (2015) The methylcytosine dioxygenase Tet2 promotes DNA demethylation and activation of cytokine gene expression in T cells. Immunity 42, 613–626.
66. Li, X., Zhang, Q., Ding, Y., Liu, Y., Zhao, D., Zhao, K., Shen, Q., Liu, X., Zhu, X., Li, N., Cheng, Z., Fan, G., Wang, Q., Cao, X. (2016) Methyltransferase Dnmt3a upregulates HDAC9 to deacetylate the kinase TBK1 for activation of antiviral innate immunity. Nat. Immunol. 17, 806–815.
67. Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., Higgins, J. M., Moltchanov, V., Kuo, F. C., Kluk, M. J., Henderson, B., Kinnunen, L., Koistinen, H. A., Ladenvall, C., Getz, G., Correa, A., Banahan, B. F., Gabriel, S., Kathiresan, S., Stringham, H. M., McCarthy, M. I., Boehnke, M., Tuomilehto, J., Haiman, C., Groop, L., Atzmon, G., Wilson, J. G., Neuberg, D., Altshuler, D., Ebert, B. L. (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498.
68. Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., Purcell, S. M., Svantesson, O., Landén, M., Höglund, M., Lehmann, S., Gabriel, S. B., Moran, J. L., Lander, E. S., Sullivan, P. F., Sklar, P., Grönberg, H., Hultman, C. M., McCarroll, S. A. (2014) Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477–2487.
69. Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., Schmidt, H. K., Yellapantula, V., Miller, C. A., Ozenberger, B. A., Welch, J. S., Link, D. C., Walter, M. J., Mardis, E. R., Dipersio, J. F., Chen, F., Wilson, R. K., Ley, T. J., Ding, L. (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20, 1472–1478.
70. Langemeijer, S. M., Mariani, N., Knops, R., Gilissen, C., Woestenenk, R., de Witte, T., Huls, G., van der Reijden, B. A., Jansen, J. H. (2016) Apoptosis-related gene expression profiling in hematopoietic cell fractions of MDS patients. PLoS One 11, e0165582.
71. Bergsbaken, T., Fink, S. L., Cookson, B. T. (2009) Pyroptosis: host cell death and inflammation. Nat. Rev. Microbiol. 7, 99–109.
72. Guo, H., Callaway, J. B., Ting, J. P. (2015) Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 21, 677–687.
73. Simard, J. C., Cesaro, A., Chapeton-Montes, J., Tardif, M., Antoine, F., Girard, D., Tessier, P. A. (2013) S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-kB(1.). PLoS One 8, e72138.
74. Basiorka, A. A., McGraw, K. L., Eksioglu, E. A., Chen, X., Johnson, J., Zhang, L., Zhang, Q., Irvine, B. A., Cluzeau, T., Sallman, D. A., Padron, E., Komrokji, R., Sokol, L., Coll, R. C., Robertson, A. A., Cooper, M. A., Cleveland, J. L., O’Neill, L. A., Wei, S., List, A. F. (2016) The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood 128, 2960–2975.
75. Miao, E. A., Rajan, J. V., Aderem, A. (2011) Caspase-1-induced pyroptotic cell death. Immunol. Rev. 243, 206–214.
76. Höckendorf, U., Yabal, M., Jost, P. J. (2016) RIPK3-dependent cell death and inflammasome activation in FLT3-ITD expressing LICs. Oncotarget 7, 57483–57484.
77. Höckendorf, U., Yabal, M., Herold, T., Munkhbaatar, E., Rott, S., Jilg, S., Kauschinger, J., Magnani, G., Reisinger, F., Heuser, M., Kreipe, H., Sotlar, K., Engleitner, T., Rad, R., Weichert, W., Peschel, C., Ruland, J., Heikenwalder, M., Spiekermann, K., Slotta-Huspenina, J., Groß, O., Jost, P. J. (2016) RIPK3 restricts myeloid leukemogenesis by promoting cell death and differentiation of leukemia initiating cells. Cancer Cell 30, 75–91.
78. Li, X., Deeg, H. J. (2014) Murine xenogeneic models of myelodysplastic syndrome: an essential role for stroma cells. Exp. Hematol. 42, 4–10.
79. Medyouf, H., Mossner, M., Jann, J. C., Nolte, F., Raffel, S., Herrmann, C., Lier, A., Eisen, C., Nowak, V., Zens, B., Müdder, K., Klein, C., Obländer, J., Fey, S., Vogler, J., Fabarius, A., Riedl, E., Roehl, H., Kohlmann, A., Staller, M., Haferlach, C., Müller, N., John, T., Platzbecker, U., Metzgeroth, G., Hofmann, W. K., Trumpp, A., Nowak, D. (2014) Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell 14, 824–837.
80. Liu, Z. J., Zhuge, Y., Velazquez, O. C. (2009) Trafficking and differentiation of mesenchymal stem cells. J. Cell. Biochem. 106, 984–991.
81. Raaijmakers, M. H., Mukherjee, S., Guo, S., Zhang, S., Kobayashi, T., Schoonmaker, J. A., Ebert, B. L., Al-Shahrour, F., Hasserjian, R. P., Scadden, E. O., Aung, Z., Matza, M., Merkenschlager, M., Lin, C., Rommens, J. M., Scadden, D. T. (2010) Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464, 852–857.
82. Kode, A., Manavalan, J. S., Mosialou, I., Bhagat, G., Rathinam, C. V., Luo, N., Khiabanian, H., Lee, A., Murty, V. V., Friedman, R., Brum, A., Park, D., Galili, N., Mukherjee, S., Teruya-Feldstein, J., Raza, A., Rabadan, R., Berman, E., Kousteni, S. (2014) Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature 506, 240–244.
83. Blau, O., Hofmann, W. K., Baldus, C. D., Thiel, G., Serbent, V., Schümann, E., Thiel, E., Blau, I. W. (2007) Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp. Hematol. 35, 221–229.
84. Kitagawa, M., Yamaguchi, S., Takahashi, M., Tanizawa, T., Hirokawa, K., Kamiyama, R. (1998) Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 12, 486–492.
85. Zhao, Z. G., Xu, W., Yu, H. P., Fang, B. L., Wu, S. H., Li, F., Li, W. M., Li, Q. B., Chen, Z. C., Zou, P. (2012) Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes. Cancer Lett. 317, 136–143.
86. Jiang, X. X., Zhang, Y., Liu, B., Zhang, S. X., Wu, Y., Yu, X. D., Mao, N. (2005) Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105, 4120–4126.
87. Zhang, W., Ge, W., Li, C., You, S., Liao, L., Han, Q., Deng, W., Zhao, R. C. (2004) Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 13, 263–271.
88. Wang, Z., Tang, X., Xu, W., Cao, Z., Sun, L., Li, W., Li, Q., Zou, P., Zhao, Z. (2013) The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromes. PLoS One 8, e57470.
89. Carty, F., Mahon, B. P., English, K. (2017) The influence of macrophages on mesenchymal stromal cell therapy: passive or aggressive agents? Clin. Exp. Immunol. 188, 1–11.
90. Mohty, M. (2007) Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 21, 1387–1394.
91. Sloand, E. M., Olnes, M. J., Shenoy, A., Weinstein, B., Boss, C., Loeliger, K., Wu, C. O., More, K., Barrett, A. J., Scheinberg, P., Young, N. S. (2010) Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J. Clin. Oncol. 28, 5166–5173.
92. Eksioglu, E. A., Chen, X., Heider, K. H., Rueter, B., McGraw, K. L., Basiorka, A. A., Wei, M., Burnette, A., Cheng, P., Lancet, J., Komrokji, R., Djeu, J., List, A., Wei, S. (2017) Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia doi:10.1038/leu.2017.21 [Epub ahead of print].
93. Epling-Burnette, P. K., McDaniel, J., Wei, S., List, A. F. (2012) Emerging immunosuppressive drugs in myelodysplastic syndromes. Expert Opin. Emerg. Drugs 17, 519–541.
94. Zhou, L., Nguyen, A. N., Sohal, D., Ying Ma, J., Pahanish, P., Gundabolu, K., Hayman, J., Chubak, A., Mo, Y., Bhagat, T. D., Das, B., Kapoun, A. M., Navas, T. A., Parmar, S., Kambhampati, S., Pellagatti, A., Braunchweig, I., Zhang, Y., Wickrema, A., Medicherla, S., Boultwood, J., Platanias, L. C., Higgins, L. S., List, A. F., Bitzer, M., Verma, A. (2008) Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood 112, 3434–3443.
95. Bachegowda, L., Morrone, K., Winski, S. L., Mantzaris, I., Bartenstein, M., Ramachandra, N., Giricz, O., Sukrithan, V., Nwankwo, G., Shahnaz, S., Bhagat, T. D., Bhattacharyya, S., Assal, A., Shastri, A., Gordon-Mitchell, S., Pellagatti, A., Boultwood, J., Schinke, C., Yu, Y., Guha, C., Rizzi, J., Garrus, J., Brown, S., Wollenberg, L., Hogeland, G., Wright, D., Munson, M., Rodriguez, M., Gross, S., Chantry, D., Zou, Y., Platanias, L. C., Burgess, L. E., Pradhan, K., Steidl, U., Verma, A. (2016) Pexmetinib: a novel dual inhibitor of Tie2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia. Cancer Res. 76, 4841–4849.
96. Navas, T., Zhou, L., Estes, M., Haghnazari, E., Nguyen, A. N., Mo, Y., Pahanish, P., Mohindru, M., Cao, T., Higgins, L. S., Platanias, L. C., List, A., Verma, A., Bhagat, T., Gajavelli, S., Kambhampati, S. (2008) Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk. Lymphoma 49, 1963–1975.
97. Garcia-Manero, G., Khoury, H. J., Jabbour, E., Lancet, J., Winski, S. L., Cable, L., Rush, S., Maloney, L., Hogeland, G., Ptaszynski, M., Calvo, M. C., Bohannan, Z., List, A., Kantarjian, H., Komrokji, R. (2015) A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin. Cancer Res. 21, 985–994.
98. List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., Zeldis, J. B. (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. 352, 549–557.
99. Corral, L. G., Haslett, P. A., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D. I., Kaplan, G. (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol. 163, 380–386.
100. Noman, A. S., Koide, N., Hassan, F., I-E-Khuda, I., Dagvadorj, J., Tumurkhuu, G., Islam, S., Naiki, Y., Yoshida, T., Yokochi, T. (2009) Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production via down-regulation of MyD88 expression. Innate Immun. 15, 33–41.
101. + cells from patients with del(5q) myelodysplastic syndrome. Haematologica 98, 409–413.
102. Stresemann, C., Lyko, F. (2008) Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer 123, 8–13.
103. Moudra, A., Hubackova, S., Machalova, V., Vancurova, M., Bartek, J., Reinis, M., Hodny, Z., Jonasova, A. (2016) Dynamic alterations of bone marrow cytokine landscape of myelodysplastic syndromes patients treated with 5-azacytidine. OncoImmunology 5, e1183860.
104. Fraison, J. B., Mekinian, A., Grignano, E., Kahn, J. E., Arlet, J. B., Decaux, O., Denis, G., Buchdahl, A. L., Omouri, M., Maigne, G., Aouba, A., Leon, N., Berthier, S., Liozon, E., Park, S., Gardin, C., Lortholary, O., Rossignol, J., Fenaux, P., Fain, O., Braun, T. (2016) Efficacy of azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk. Res. 43, 13–17.
105. Mekinian, A., Grignano, E., Braun, T., Decaux, O., Liozon, E., Costedoat-Chalumeau, N., Kahn, J. E., Hamidou, M., Park, S., Puéchal, X., Toussirot, E., Falgarone, G., Launay, D., Morel, N., Trouiller, S., Mathian, A., Gombert, B., Schoindre, Y., Lioger, B., De Wazieres, B., Amoura, Z., Buchdaul, A. L., Georgin-Lavialle, S., Dion, J., Madaule, S., Raffray, L., Cathebras, P., Piette, J. C., Rose, C., Ziza, J. M., Lortholary, O., Montestruc, F., Omouri, M., Denis, G., Rossignol, J., Nimubona, S., Adès, L., Gardin, C., Fenaux, P., Fain, O. (2016) Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford) 55, 291–300.
106. Thangavel, J., Samanta, S., Rajasingh, S., Barani, B., Xuan, Y. T., Dawn, B., Rajasingh, J. (2015) Epigenetic modifiers reduce inflammation and modulate macrophage phenotype during endotoxemia-induced acute lung injury. J. Cell Sci. 128, 3094–3105.
107. Cao, Q., Wang, X., Jia, L., Mondal, A. K., Diallo, A., Hawkins, G. A., Das, S. K., Parks, J. S., Yu, L., Shi, H., Shi, H., Xue, B. (2014) Inhibiting DNA methylation by 5-Aza-2'-deoxycytidine ameliorates atherosclerosis through suppressing macrophage inflammation. Endocrinology 155, 4925–4938.
108. Stübig, T., Badbaran, A., Luetkens, T., Hildebrandt, Y., Atanackovic, D., Binder, T. M., Fehse, B., Kröger, N. (2014) 5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity. Mediators Inflamm. 2014, 418292.
109. Riddle, M. C. (2003) Editorial: sulfonylureas differ in effects on ischemic preconditioning–is it time to retire glyburide? J. Clin. Endocrinol. Metab. 88, 528–530.
110. Lamkanfi, M., Mueller, J. L., Vitari, A. C., Misaghi, S., Fedorova, A., Deshayes, K., Lee, W. P., Hoffman, H. M., Dixit, V. M. (2009) Glyburide inhibits the cryopyrin/Nalp3 inflammasome. J. Cell Biol. 187, 61–70.
111. Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., Mullooly, N., Mielke, L. A., Harris, J., Coll, R. C., Mills, K. H., Mok, K. H., Newsholme, P., Nuñez, G., Yodoi, J., Kahn, S. E., Lavelle, E. C., O’Neill, L. A. (2010) Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat. Immunol. 11, 897–904.
112. Fowler, B. J., Gelfand, B. D., Kim, Y., Kerur, N., Tarallo, V., Hirano, Y., Amarnath, S., Fowler, D. H., Radwan, M., Young, M. T., Pittman, K., Kubes, P., Agarwal, H. K., Parang, K., Hinton, D. R., Bastos-Carvalho, A., Li, S., Yasuma, T., Mizutani, T., Yasuma, R., Wright, C., Ambati, J. (2014) Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity. Science 346, 1000–1003.
113. + release. Am. J. Physiol. Cell Physiol. 286, C1100–C1108.
114. Zhang, X. J., Zheng, G. G., Ma, X. T., Yang, Y. H., Li, G., Rao, Q., Nie, K., Wu, K. F. (2004) Expression of P2X7 in human hematopoietic cell lines and leukemia patients. Leuk. Res. 28, 1313–1322.
115. Juliana, C., Fernandes-Alnemri, T., Wu, J., Datta, P., Solorzano, L., Yu, J. W., Meng, R., Quong, A. A., Latz, E., Scott, C. P., Alnemri, E. S. (2010) Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J. Biol. Chem. 285, 9792–9802.
116. Natarajan-Amé, S., Park, S., Ades, L., Vey, N., Guerci-Bresler, A., Cahn, J. Y., Etienne, G., Bordessoule, D., Ravoet, C., Legros, L., Cheze, S., Stamatoullas, A., Berger, E., Schmidt, A., Charbonnier, A., Chaury, M. P., Braun, T., Fenaux, P., Dreyfus, F.; Groupe Francophone des Myélodysplasies (GFM). (2012) Bortezomib combined with low-dose cytarabine in intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM. Br. J. Haematol. 158, 232–237.
117. Terpos, E., Verrou, E., Banti, A., Kaloutsi, V., Lazaridou, A., Zervas, K. (2007) Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis. Leuk. Res. 31, 559–562.
118. Daher, M., Hidalgo Lopez, J. E., Randhawa, J. K., Jabbar, K. J., Wei, Y., Pemmaraju, N., Borthakur, G., Kadia, T., Konopleva, M., Kantarjian, H. M., Hearn, K., Estrov, Z., Reyes, S., Bueso-Ramos, C. E., Garcia-Manero, G. (2017) An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am. J. Hematol. doi:10.1002/ajh.24746 [Epub ahead of print].
119. Isakov, E., Weisman-Shomer, P., Benhar, M. (2014) Suppression of the pro-inflammatory NLRP3/interleukin-1β pathway in macrophages by the thioredoxin reductase inhibitor auranofin. Biochim. Biophys. Acta 1840, 3153–3161.
120. He, Y., Varadarajan, S., Muñoz-Planillo, R., Burberry, A., Nakamura, Y., Núñez, G. (2014) 3,4-Methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J. Biol. Chem. 289, 1142–1150.
121. Maier, N. K., Leppla, S. H., Moayeri, M. (2015) The cyclopentenone prostaglandin 15d-PGJ2 inhibits the NLRP1 and NLRP3 inflammasomes. J. Immunol. 194, 2776–2785.
122. Coll, R. C., Robertson, A., Butler, M., Cooper, M., O’Neill, L. A. (2011) The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PLoS One 6, e29539.
123. Coll, R. C., Robertson, A. A., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., Croker, D. E., Butler, M. S., Haneklaus, M., Sutton, C. E., Núñez, G., Latz, E., Kastner, D. L., Mills, K. H., Masters, S. L., Schroder, K., Cooper, M. A., O’Neill, L. A. (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21, 248–255.
124. Honda, H., Nagai, Y., Matsunaga, T., Okamoto, N., Watanabe, Y., Tsuneyama, K., Hayashi, H., Fujii, I., Ikutani, M., Hirai, Y., Muraguchi, A., Takatsu, K. (2014) Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation. J. Leukoc. Biol. 96, 1087–1100.